Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Crispr Therapeutics AG (CRSP) vs Clear Secure Inc (YOU) Price & Performance

Crispr Therapeutics AGTrade
Clear Secure IncTrade

Price performance (Past 24H)

Key statistics

Crispr Therapeutics AG vs Clear Secure Inc — how do they compare? Crispr Therapeutics AG trades at $54.3 (market cap $5.23B), while Clear Secure Inc trades at $48 (market cap $4.98B). The key difference: Crispr Therapeutics AG and Clear Secure Inc are close in size by market cap, and Clear Secure Inc pays a 1.19% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.

CRSPYOU
Market Cap
$5.23B$4.98B
Sector
HealthTechnology
52-Week High
$76.78$62.36
52-Week Low
$44.34$29.61
Enterprise Value
$3.65B$4.13B
Dividend Yield
1.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Crispr Therapeutics AG

CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.

Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.

Clear Secure Inc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP

About Clear Secure Inc

Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.

Read more on YOU